{"schema_version":"secwatch.filing_event.v1","accession":"0001326190-23-000025","form_type":"8-K","ticker":"ALT","cik":"0001326190","company_name":"Altimmune, Inc.","filed_at":"2023-05-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:38.407260+00:00","generated_at":"2026-06-15T03:43:26.043322+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Altimmune reports Q1 net loss $20.1M; pemvidutide NASH trial initiation mid-2023","bullets":["Net loss of $20.1M ($0.40/share) vs $19.4M ($0.44/share) in Q1 2022; R&D expenses $17.2M.","Cash $165.8M at March 31, 2023; MOMENTUM obesity trial 48-week top-line results expected Q4 2023.","Pemvidutide 24-week data: 10.7% (2.4mg) and 9.4% (1.8mg) mean weight loss; ~50% achieved ≥10% loss.","IMPACT Phase 2b NASH trial (~190 subjects) to start mid-2023; top-line results expected Q1 2025.","HepTcell Phase 2 CHB trial fully enrolled (~80 subjects); top-line results expected Q1 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001326190-23-000025","json":"https://secwatch.observer/filing/0001326190-23-000025.json","markdown":"https://secwatch.observer/filing/0001326190-23-000025.md","text":"https://secwatch.observer/filing/0001326190-23-000025.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1326190/000132619023000025/0001326190-23-000025-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1326190/000132619023000025/alt-20230511x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T03:43:26.043322+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"09872071a6ff8544c7e5709a3f5a42ea07b21069","claim":"Altimmune, Inc. reported three months ended March 31, 2023 results: net income $20.1 million, EPS $0.40 net loss per share.","evidence_excerpt":"Net loss for the three months ended March 31, 2023 was $20.1 million, or $0.40 net loss per share, compared to a net loss of $19.4 million, or $0.44 net loss per share, in the same period in 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1326190/000132619023000025/0001326190-23-000025-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"three months ended March 31, 2023"},{"label":"Net income","value":"$20.1 million"},{"label":"EPS","value":"$0.40 net loss per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}